Abstract
Objective. We aimed to evaluate the prognostic value of circulating galectin-3 for cumulative survival in patients with multiple myeloma in full or partial remission.Materials and methods. Eighty nine subjects with multiple myeloma in full or partial remission were enrolled into the study. Observation period was up to 12 months. Blood samples for biomarkers measurements were collected. Circulating level of galectin-3 was measured with ELISA method.Results and Conclusions. Ninety two cumulative clinical events occurred in 36 patients (40.5%) within the follow-up, with their distribution being as follows: 8 cardiovascular deaths, 46 cardiac arrhythmias, 8 cardiac ischemic events, 2 strokes, 8 chronic heart failures and 22 hospital admissions for cardiovascular reasons. Medians of circulating levels of galectin-3 in free-events subject cohort and subjects cohort with cardiovascular events were 5.17 ng/ml (95% confidence interval [CI]=2.87–7.78 ng/ml) and 17.57 ng/ml (95% CI=11.36–23.79 ng/ml) (р<0.001). In multivariate logistic regression circulating galectin-3 independently predicted cumulative cardiovascular events (odds ratio [OR]=1.10; 95% CI=1.01–1.13; р = 0.001) within 12 months of observation period.Among patients with documented multiple myeloma in remission increased circulating galectin-3 associates with increased cumulative cardiovascular events.
Highlights
Цель исследования – изучение прогностической значимости циркулирующего галектина-3 в возникновении кардиоваскулярных событий, выживаемости пациентов со множественной миеломой в ремиссии
Медиана циркулирующего галектина-3 у пациентов без кардиоваскулярных событий составила 5,17 нг/мл (95% доверительный интервал [ДИ]=2,87–7,48 нг/мл) и 17,57 нг/мл (95% ДИ=11,36–23,79 нг/мл) соответственно, (р
We aimed to evaluate the prognostic value of circulating galectin-3 for cumulative survival in patients with multiple myeloma in full or partial remission
Summary
Цель исследования – изучение прогностической значимости циркулирующего галектина-3 в возникновении кардиоваскулярных событий, выживаемости пациентов со множественной миеломой в ремиссии. Зафиксировано 92 кардиоваскулярных события у 36 пациентов (40,5%): 8 смертей вследствие кардиоваскулярной причины, 46 кардиальных аритмий, 6 кардиальных ишемических событий, 2 инсульта, 8 случаев возникновения хронической сердечной недостаточности, 22 госпитализации, связанных с кардиоваскулярными причинами. Медиана циркулирующего галектина-3 у пациентов без кардиоваскулярных событий составила 5,17 нг/мл (95% доверительный интервал [ДИ]=2,87–7,48 нг/мл) и 17,57 нг/мл (95% ДИ=11,36–23,79 нг/мл) соответственно, (р
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.